---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-009540"
form_type: "8-K/A"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T14:46:31.760886+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma files merger financials: 2021 revenue $5.5M, net loss $20.2M

## Summary
- Audited 2021 revenue $5.5M vs $17.8M in 2020; net loss $20.2M vs $1.1M.
- Cash $60.1M at Dec 31, 2021; accumulated deficit $42.3M; expects continued losses.
- Product candidate ARS-1 (Neffy) for needle-free epinephrine in anaphylaxis.
- Merger with Silverback closed Nov 2022; this amendment provides previously missing financials.
- Pro forma combined financials filed as Exhibit 99.3; shows combined entity post-merger.

## SEC filing metadata
- accession: 0001193125-23-009540
- form_type: 8-K/A
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/0001193125-23-009540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312523009540/d448105d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-009540
- JSON: https://secwatch.observer/filing/0001193125-23-009540.json
- Plain text: https://secwatch.observer/filing/0001193125-23-009540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.